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Abstract
Background: The frequency of a variant in the general population is a key criterion used in the clinical interpretation
of sequence variants. With certain exceptions, such as founder mutations, the rarity of a variant is a prerequisite for
pathogenicity. However, defining the threshold at which a variant should be considered “too common” is challenging
and therefore diagnostic laboratories have typically set conservative allele frequency thresholds.
Methods: Recent publications of large population sequencing data, such as the Exome Aggregation Consortium
(ExAC) database, provide an opportunity to characterize with accuracy and precision the frequency distributions of very
rare disease-causing alleles. Allele frequencies of pathogenic variants in ClinVar, as well as variants expected to be
pathogenic through the nonsense-mediated decay (NMD) pathway, were analyzed to study the burden of pathogenic
variants in 79 genes of clinical importance.
Results: Of 1364 BRCA1 and BRCA2 variants that are well characterized as pathogenic or that are expected to lead to
NMD, 1350 variants had an allele frequency of less than 0.0025%. The remaining 14 variants were previously published
founder mutations. Importantly, we observed no difference in the distributions of pathogenic variants expected to be
lead to NMD compared to those that are not. Therefore, we expanded the analysis to examine the distributions of
NMD expected variants in 77 additional genes. These 77 genes were selected to represent a broad set of clinical areas,
modes of inheritance, and penetrance. Among these variants, most (97.3%) had an allele frequency of less than 0.01%.
Furthermore, pathogenic variants with allele frequencies greater than 0.01% were well characterized in publications
and included many founder mutations.
Conclusions: The observations made in this study suggest that, with certain caveats, a very low allele frequency
threshold can be adopted to more accurately interpret sequence variants.
Keywords: Allele-frequency threshold, Variant interpretation, ExAC, ACMG ISV guidelines
Background
With the increasing adoption of whole-genome, exome,
and panel-based genetic testing, the detection of novel,
previously uncharacterized sequence variants has in-
creased dramatically. Currently, approximately 85% of
sequence variants in ClinVar have been reported only by
single submitters and, despite growth in both the num-
ber of ClinVar participants and total entries, this per-
centage has remained steady [1]. We have undoubtedly
entered an era in which detection of variants far out-
paces the ability of researchers to gather genetic data or
generate experimental data to assess potential pheno-
typic consequences. With such limited data, more than
40% of the variants in ClinVar are still designated as var-
iants of uncertain significance.
One class of empirical data, however, has great poten-
tial for improving variant interpretation: population al-
lele frequency data. According to the joint consensus
recommendation for the interpretation of sequence vari-
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Genomics (ACMG) and the Association for Molecular
Pathology (AMP), an “allele frequency greater than ex-
pected for disorder” is strong evidence for a benign clas-
sification [2]. However, the recommendation provides no
detailed guidance for determining the expected allele
frequency of pathogenic variants. Furthermore, most
population databases do not provide phenotypic
information on individuals included and are rarely a col-
lection of individuals unburdened with disease. Under-
standing and accounting for this fact is critical in
determining the frequency threshold at which a variant
can be considered “greater than expected for disorder.”
After the release of the Exome Variant Server (EVS)
dataset, Norton et al. [3] and Shearer et al. [4] proposed
and explored strategies for using the allele frequency of
known pathogenic variants to determine a disease-
specific MAF threshold. These approaches were power-
ful in supporting a dramatic reduction in MAF thresh-
olds for two diseases; however, their applications are
limited to genes for which high-quality curated lists of
pathogenic variants are available. Furthermore, the use-
fulness of such data for clinical variant interpretation
was limited because allele frequencies were calculated
using small datasets, resulting in frequency estimates of
limited accuracy.
This situation changed significantly with the publica-
tion of the Exome Aggregation Consortium (ExAC)
population dataset comprising exome sequencing data
from 60,706 unrelated individuals [5]—a nearly tenfold
increase in the data compared to previously available
population databases. This dramatic increase in cohort
size results in a more comprehensive representation of
very rare variants and allows for more accurate minor al-
lele frequency (MAF) calculations. These advantages
allow for the direct and accurate characterization of the
population burden of pathogenic variants associated
with rare Mendelian disorders [5–8]. Such characteriza-
tions, in turn, can be used to measure the likelihood of
whether a novel, previously uncharacterized variant is
too common to be consistent with what is expected of
pathogenic variants in this cohort (Fig. 1).
In this study, we sought to develop a method for de-
termining MAF thresholds that does not rely on com-
prehensive, curated lists of pathogenic variants. To do
so, we began by exploring the population burden of rep-
resentative pathogenic variants in the ExAC cohort. Spe-
cifically, we examined the distributions of known
pathogenic variants in BRCA1 and BRCA2 (BRCA1/
2)—well-characterized genes with loss-of-function mo-
lecular mechanisms—and showed that the frequency of
pathogenic variants in the ExAC dataset is very low,
does not depend on variant type, and is consistent with
disease incidence in the general population. We then ap-
plied an analysis of the frequency of premature-
A
B C
Fig. 1 Concept diagram for using pathogenic variant frequency distributions to establish allele frequency thresholds. Depicted is a density plot of
pathogenic variants in a hypothetical gene. x-axis: allele frequency; y-axis: number of pathogenic variants. The arrows (labeled A, B, and C) highlight
three different scenarios of how allele frequencies of previously uncharacterized variants can be evaluated in the context of the pathogenic variant
frequency distribution. In scenario A, the uncharacterized variant has an allele frequency that is highly consistent with known pathogenic variants.
Because many benign variants are also rare or private, the allele frequency of this variant provide little weight towards either classification. In scenario
B, the uncharacterized variant has an allele frequency that is consistent with known pathogenic variants, but is more common than the vast majority
of them. The likelihood of such a variant being pathogenic is substantially reduced. In scenario C, the uncharacterized variant has an allele frequency
outside of the pathogenic variant frequency distribution. The likelihood of such a variant being pathogenic is extremely low, as it is more common
than any other previously characterized pathogenic variant
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termination variants to 77 other genes, including genes
associated with hereditary cancer, genes with autosomal
recessive inheritance patterns, genes with substantially
reduced penetrance, and to a set of genes that are gener-
ally less well studied. This empirical approach to identi-
fying the frequency characteristics of pathogenic variants
supports the use of ExAC to calculate of MAF thresh-
olds that are substantially lower than current industry
norms for a broad set of genes.
Methods
ExAC data processing
Version 0.3 of the ExAC dataset was used as a data
source in this study [9]. Only variants with the ExAC
bioinformatics filter status of “PASS” were included in
the analysis. Furthermore, to ensure adequate population
depth for accurate allele frequency calculations, we re-
stricted our analyses to loci with a minimum cohort
depth of 80,000 total alleles (AN_Adj). The “AC_Adj”
data points were used for allele counts.
To identify variants expected to lead to nonsense-
mediated decay (NMDpositive), we started with variants
designated by ExAC as “HC” (high-confidence) loss-of-
function (nonsense, frameshift and consensus splice site
variants). We further filtered variants to exclude those
that are not expected to be subject to NMD; specifically,
a variant was removed if the predicted premature-
termination codon occurred in the final exon, within
50 bp of the final exon − exon junction, or as part of the
consensus splice site dinucleotide in the final intron
[10]. Also removed were variants with published experi-
mental data indicating that they escaped NMD. Add-
itionally, analyses were restricted to NMD predictions
relative to clinically relevant transcripts. Clinically rele-
vant transcripts were determined based on reviews of
the Human Genome Mutation Database (HGMD) [11]
and published literature (see Additional file 4). Variants
were designated as NMDnegative if they do not meet the
criteria for NMDpositive. These include: missense vari-
ants, synonymous variants, intronic variants beyond the
consensus splice site dinucleotides, in-frame indels, and
truncating variants that are not expected to lead to
NMD.
ClinVar data processing
The January 2016 ClinVar Full Release XML file was
used as a data source in this study [12]. To avoid dubi-
ous variant classification calls, we restricted the analyses
to interpretations from a subset of the submitters (see
Additional file 5).
For the evaluation of pathogenic NMDnegative variants
in BRCA1/2, variants were included if they had a unani-
mous consensus classification of pathogenic or likely
pathogenic from multiple submitters. NMDnegative
variants classified pathogenic or likely pathogenic by a
single submitter or lacking consensus among multiple
submitters were evaluated based on the 2015 ACMG
guidelines for the interpretation of sequence variants [4].
Variants were included if the pathogenic or likely patho-
genic classification was attained with this method.
Variant classifications from HGMD were not consid-
ered in this, as many disease-associated variants in that
dataset have been shown not to be causative [13–15].
Identifying published literature for variants
To identify a comprehensive list of publications for a
given variant, searches were performed with several data
sources and search tools including HGMD, ClinVar,
SETH, NCBI PubTator, and Google. Variants described
at the DNA and protein levels, with considerations for
both legacy naming and HGVS nomenclature, were used
as search terms.
Results
Historically, small cohorts of presumed healthy individ-
uals have been used to distinguish benign polymor-
phisms from potentially pathogenic variants. This
approach is effective for early-onset dominant disorders
with high penetrance, as any variants observed in un-
affected individuals are unlikely to be disease causing. By
contrast, modern population datasets such as ExAC and
EVS are typically aggregates of multiple large-scale se-
quencing projects and often include individuals recruited
for disease-specific studies [3, 5]. Therefore, the likeli-
hood is high that disease-causing variants are present in
these cohorts. This likelihood increases even further
when one considers low-penetrance, late-onset, or reces-
sive disorders in which unaffected carriers are expected
to be present. The clinical utility of large population da-
tabases in variant interpretation is contingent on ac-
counting for the presence of these variants. To this end,
we first evaluated the prevalence of pathogenic variants
in ExAC for a number of well-studied genes.
Allele frequency distributions of pathogenic variants in
BRCA1/2
We first evaluated the frequency of pathogenic variants
in BRCA1/2, genes that are known to cause hereditary
breast and ovarian cancer (HBOC) [16, 17]. BRCA1/2
are among the most well studied and clinically tested
genes and there is little disagreement about the patho-
genicity of most variants [18]. These characteristics gave
us high confidence that the catalog of observed patho-
genic variants is nearly comprehensive for recurrent var-
iants and largely uncontroversial. We expect to find
many unaffected carriers in the general population be-
cause the prevalence of HBOC is relatively high [19, 20],
the disease has an adult onset, and pathogenic BRCA1/2
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variants are incompletely penetrant [21, 22], particularly
in male carriers. Finally, because more than one-tenth of
the ExAC population was derived from The Cancer
Genome Atlas (TCGA) patient cohort [5], the ExAC
dataset might contain an enrichment of pathogenic vari-
ants compared to the general population.
In total, there were 592 BRCA1 and 712 BRCA2
unique pathogenic variants in ClinVar. An additional 60
variants that were present in ExAC, but not in ClinVar,
and are expected to be pathogenic based on variant type,
were also included in the analysis. These variants in-
cluded nonsense or frameshift variants that are suffi-
ciently 5′ in the gene to be expected to subject the
messenger RNA transcript to NMD [10], and therefore
loss of protein expression, and variants that are part of
the consensus splice donor or acceptor dinucleotides
[23]. These types of variants were collectively designated
as NMDpositive variants, while those that are not ex-
pected to lead to NMD were designated as NMDnegative
variants. The vast majority of pathogenic variants were
extremely rare: of the total 1364 pathogenic variants,
1163 (85.3%) were absent from the ExAC cohort and an
additional 150 (11.0%) were each observed in ExAC in a
single individual (Fig. 2). All 60 of the non-ClinVar
NMDpositive variants found in ExAC were among those
observed only in single individuals (Additional file 1).
From the perspective of allele frequencies, 1356/1364
(99.4%) of the pathogenic variants had allele frequencies
of less than 0.005%. The difference in the frequencies of
pathogenic variants compared to frequencies of all
BRCA1/2 variants in ExAC was statistically significant
(p < 8.5E-11; Wilcoxon rank-sum test).
ExAC also contains 14 pathogenic variants observed in
more than three individuals. All of these have been
A
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Fig. 2 Allele counts of BRCA1 and BRCA2 pathogenic and likely pathogenic variants. Histograms of the allele counts of pathogenic and likely
pathogenic variants in the ExAC dataset for (a) BRCA1 and (b) BRCA2. x-axis: allele count; y-axis: number of unique sequence variants. The red
portion represents pathogenic NMDpositive variants and the orange portion represents pathogenic NMDnegative variants (missense, intronic,
in-frame indels, and truncations expected to avoid NMD)
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reported as population-specific founder mutations or
have been otherwise well characterized in the literature
as common recurrent variants (Table 1). Excluding these
variants, the next most common variant was present at a
frequency of 0.0025%. The most common founder muta-
tion, BRCA2 c.5946delT (p.Ser1982Argfs*22) [24], was
present at a frequency of 0.027%.
We compared the frequency distributions of pathogenic
NMDpositive variants to that of pathogenic NMDnegative
variants and found no statistically significant difference:
Wilcoxon rank-sum test failed to reject the null hypoth-
esis that the distributions of NMDpositive and NMDnegative
pathogenic variants are equal (p = 0.72). A few missense
variants in BRCA1 had previously been characterized
as being hypomorphic [25], which raised the possibil-
ity that they might have been present at allele fre-
quencies higher than those of null variants. This does
not appear to be the case, however. For the two puta-
tively hypomorphic missense variants examined,
p.Ser1497Ala was absent in the ExAC cohort and
p.Arg1699Gln was observed in three individuals. One
missense variant, p.Cys61Gly, that was previously re-
ported as a founder mutation in multiple ethnic
groups was observed in eight individuals [25]. These
observations suggest that an analysis of pathogenic
NMDpositive variants can provide conclusions repre-
sentative of all variant types.
Allele frequency distributions of NMDpositive variants in
other clinically relevant genes
In the analysis of BRCA1/2 variants we noted that there
was no apparent enrichment for observations of
pathogenic NMDnegative variants compared with patho-
genic NMDpositive variants and that even known hypo-
morphic missense variants were present at very low
allele frequencies. These observations suggest that for
genes with loss-of-function mechanisms of disease, a
pathogenic allele frequency distribution determined by
only NMDpositive variants can serve as a close approxi-
mation of the comprehensive set of pathogenic variants
(Additional file 1). Based on this observation, we ex-
panded our analysis to several dozen clinically relevant
genes across multiple clinical areas where the disease
mechanism has been established as loss of function
(Table 2).
We initially examined 31 additional genes associated
with hereditary cancer syndromes. These genes are also
associated with adult-onset conditions with incomplete
penetrance. Consistent with the observations in BRCA1/
2, NMDpositive variants in these genes were rare, and the
vast majority (576/591) had allele frequencies of less
than 0.01%. Only two variants were reported at allele
frequencies greater than 0.05%: CHEK2 c.1100delC, a
well-characterized Northern European founder mutation
[26]; and MUTYH c.934-2A > G, a splice-site variant
previously reported to have a high carrier frequency in
individuals of East Asian descent [27]. Including these
two variants, 15 total variants had allele frequencies
greater than 0.01%, of which eight have been reported as
founder or suspected founder mutations.
Next, we examined genes suspected for various rea-
sons to harbor higher frequencies of pathogenic variants
in the ExAC database. We analyzed 25 genes that cause
primary ciliary dyskinesia (PCD), as these genes have a
Table 1 Most common pathogenic BRCA1 and BRCA2 variants in ExAC
Gene Variant Effect Allele count MAF Type
BRCA1 NM_007294.3:c.68_69delAG p.Glu23Valfs*17 29 0.024% Founder [24]
BRCA1 NM_007294.3:c.5266dupC p.Gln1756Profs*74 19 0.016% Founder [24]
BRCA1 NM_007294.3:c.181 T > G p.Cys61Gly 8 0.0067% Founder [36]
BRCA1 NM_007294.3:c.4035delA p.Glu1346Lysfs*20 5 0.0041% Founder [37]
BRCA1 NM_007294.3:c.1687C > T p.Gln563* 5 0.0041% Founder [38]
BRCA2 NM_000059.3:c.5946delT p.Ser1982Argfs*22 32 0.027% Founder [24]
BRCA2 NM_000059.3:c.3847_3848delGT p.Val1283Lysfs*2 11 0.011% Recurrent [39]
BRCA2 NM_000059.3:c.658_659delGT p.Val220Ilefs*4 6 0.0061% Recurrent [40, 41]
BRCA2 NM_000059.3:c.7480C > T p.Arg2494* 6 0.0050% Founder [42]
BRCA2 NM_000059.3:c.3545_3546delTT p.Phe1182* 4 0.0033% Recurrent [43, 44]
BRCA2 NM_000059.3:c.3599_3600delGT p.Cys1200* 4 0.0033% Recurrent [45]
BRCA2 NM_000059.3:c.5576_5579delTTAA p.Ile1859Lysfs*3 4 0.0033% Recurrent [46, 47]
BRCA2 NM_000059.3:c.7069_7070delCT p.Leu2357Valfs*2 4 0.0033% Recurrent [48]
BRCA2 NM_000059.3:c.9118-2A > G Splice acceptor 4 0.0033% Recurrent [39, 49]
Fourteen pathogenic variants in BRCA1 and BRCA2 were observed in more than three individuals in the ExAC cohort. All of these variants have been previously
reported as founder or common recurrent variants. Some of these recurrent variants are suggested to be founder mutations, but have not been confirmed as
such. MAF minor allele frequency
Kobayashi et al. Genome Medicine  (2017) 9:13 Page 5 of 14
Table 2 Frequencies of NMDpositive variants in hereditary cancer,
primary ciliary dyskinesia (PCD), and arrhythmia/cardiomyopathy
genes in ExAC
Variant allele frequencies in ExAC:








APC Dominant 6 - - - -
ATM Recessive 104 1 - - -
BARD1 Dominant 22 - - - -
BLM Recessive 38 2 1 - -
BMPR1A Dominant 3 1 - - -
BRCA1 Dominant 67 - 2 - -
BRCA2 Dominant 103 2 1 - -
BRIP1 Recessive 32 - 1 - -
CDH1 Dominant 5 - - - -
CDKN2A Dominant 4 - - - -
CHEK2 Dominant 29 3 2 - 1
CTRC Dominant 11 1 - - -
EPCAM Recessive 9 1 - - -
FANCC Recessive 23 1 - - -
MEN1 Dominant - - - - -
MLH1 Dominant 5 - - - -
MRE11A Recessive 18 1 - - -
MSH2 Dominant 7 1 - - -
MSH6 Dominant 25 - 1 - -
MUTY Recessive 19 3 2 - 1
NBN Recessive 33 1 1 - -
NF1 Dominant 23 1 - - -
PALB2 Dominant 35 2 1 - -
PMS2 Dominant 32 - - - -
PTCH1 Dominant 2 - - - -
PTEN Dominant 2 - - - -
RAD50 Recessive 42 2 3 - -
RAD51C Recessive 19 3 - - -
SMAD4 Dominant 2 - - - -
SPINK1 Dominant 1 - 1 - -
STK11 Dominant - - - - -
TP53 Dominant 1 - - - -
VHL Dominant - - - - -
Primary ciliary dyskinesia
ARMC4 Recessive 36 3 - - -
C21orf59 Recessive 7 1 1 - -
CCDC103 Recessive 3 - - - -
CCDC114 Recessive 6 - - - -
Table 2 Frequencies of NMDpositive variants in hereditary cancer,
primary ciliary dyskinesia (PCD), and arrhythmia/cardiomyopathy
genes in ExAC (Continued)
CCDC151 Recessive 16 1 - - -
CCDC39 Recessive 22 2 - - -
CCDC40 Recessive 32 1 1 - -
CCDC65 Recessive 17 - 1 - -
CCNO Recessive - - - - -
DNAAF1 Recessive 19 2 1 - -
DNAAF2 Recessive 12 - - - -
DNAAF3 Recessive 16 2 1 - -
DNAH11 Recessive 80 1 2 - -
DNAH5 Recessive 113 - 2 - -
DNAI1 Recessive 15 - 1 - -
DNAI2 Recessive 21 1 1 - -
DNAL1 Recessive 3 - - - -
DRC1 Recessive 22 - 2 - -
DYX1C1 Recessive 18 1 - - -
RPGR Recessive 1 - - - -
RSPH1 Recessive 9 1 2 - -
RSPH4A Recessive 27 1 - - -
RSPH9 Recessive 4 - - - -
SPAG1 Recessive 21 2 - - -
ZMYND10 Recessive 16 - - - -
Arrhythmia and cardiomyopathy
BAG3 Dominant 2 - - - -
CACNA1C Dominant 6 - - - -
CASQ2 Recessive 15 - - - -
DES Recessive 5 - - - -
DSC2 Dominant 13 - - - -
DSG2 Dominant 19 - - - -
DSP Recessive 21 - - - -
FHL1 Dominant - - - - -
HCN4 Dominant 5 - - - -
JUP Recessive 7 - - - -
KCNE1 Dominant - - - - -
KCNH2 Dominant 5 - 2 - -
KCNQ1 Dominant 15 - 1 - -
LAMP2 Dominant - - - - -
LMNA Dominant 1 - - - -
MYBPC3 Dominant 17 - - - -
NKX2-5 Dominant 1 - - - -
PKP2 Dominant 18 - 1 - -
PLN Dominant - - - - -
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recessive mode of inheritance and the presence of un-
affected heterozygous carriers are likely to result in
higher allele frequencies of pathogenic variants. In
addition, because the single largest cohort within ExAC
was derived from the Myocardial Infarction Genetics
Consortium [5]—which may result in enrichment for
pathogenic variants in cardiology-related genes—we ana-
lyzed 21 genes known to cause arrhythmias and cardio-
myopathies through loss-of-function mechanisms.
Among the 742 NMDpositive variants across these 46
genes, none reached an allele frequency greater than
0.05%. For the PCD genes, seven of the 15 NMDpositive
variants with allele frequencies greater than 0.01% were
previously published as founder or suspected founder
mutations. For the genes associated with arrhythmias
and cardiomyopathies, only six NMDpositive variants had
allele frequencies greater than 0.01%, one of which is a
known founder mutation (Additional file 2). Interest-
ingly, NMDpositive variants in five gain-of-function car-
diomyopathy and arrhythmia genes were also very rare
with 93 of 96 such variants being present at less than
0.005% frequency. This is consistent with the under-
standing that even benign variants are often very rare.
Strikingly, however, the ABCC9 gene contained two
NMDpositive variants that were present in greater than
0.01%: c.565C > T (p.Arg189*) at 0.013% and c.2238-
1G > A at 0.16% (Additional file 3).
Because there are many other cardiomyopathy-
associated and arrhythmia-associated genes in which the
disease mechanism is gain-of-function, this analysis
alone cannot eliminate the possibility that the ExAC co-
hort is enriched for individuals with pathogenic NMDne-
gative variants in those genes. To examine this possibility
further, we analyzed previously classified missense vari-
ants. However, compared with BRCA1/2, these genes
accounted for substantially fewer submissions to Clin-
Var. Therefore, we referred to a previously published
“gold standard” set of 74 missense variants from six
genes associated with hypertrophic cardiomyopathy [28].
This set, which was published before the release of the
ExAC dataset, includes 41 pathogenic missense variants
and 33 benign or likely benign missense variants
(Table 3). Of the pathogenic missense variants, 29 were
not observed in the ExAC cohort. The most common
pathogenic missense variant was MYH7 c.2389G > A
(p.Ala797Thr), which was observed with an allele fre-
quency of 0.0033%. The MYBPC3 variant c.1504C > T
(p.Arg502Trp) is considered one of the most common
pathogenic variants of hypertrophic cardiomyopathy in
individuals of European descent [29] and it was observed
with an allele frequency of 0.0025%.
Two common themes emerged from our analysis of all
of the genes we evaluated: (1) the vast majority of patho-
genic variants were extremely rare (allele frequency less
than 0.01%); and (2) variants with allele frequencies
above 0.01% were generally already well characterized in
the literature. We speculate that these outliers reached
elevated allele frequencies owing to mutational hot spot
effects or population history, such as bottleneck events.
Consistent with this speculation, no correlation was ob-
served between the number of outliers or the allele fre-
quencies of outliers and disease severity, penetrance, or
inheritance pattern.
Accounting for outlier-frequency pathogenic variants
through literature review
Without careful consideration, aggressive allele fre-
quency thresholds may increase the risk of incorrectly
classifying pathogenic variants with elevated allele fre-
quencies as benign. However, this problem is neither
unique nor new, as many in the clinical genetics com-
munity currently adopt thresholds lower than the MAFs
of many founder mutations. Well-known examples in-
clude two BRCA1/2 variants observed at MAFs of 1% in
the Ashkenazi Jewish population (BRCA1 c.68_69delAG
and BRCA2 c.5946_5949delTGGA) [24] and the CFTR
ΔF508 variant observed at 1% frequency in the European
population [30, 31]. Because these variants are by def-
inition frequently observed, they are typically accom-
panied by many published studies that support a
pathogenic classification despite the greater than ex-
pected frequency.
To assess whether a thorough literature review would
be sufficient to identify outlier-frequency pathogenic var-
iants, we measured publication counts for this type of
variant. Specifically, variants with allele frequencies
greater than 0.01% and ClinVar consensus classifications
of pathogenic (two or more submitters all agreeing on
designations of pathogenic or likely pathogenic) were
evaluated. Among all of the entries in ClinVar—span-
ning thousands of genes—only 129 variants from 79
genes met these criteria and each of these 129 consensus
Table 2 Frequencies of NMDpositive variants in hereditary cancer,
primary ciliary dyskinesia (PCD), and arrhythmia/cardiomyopathy
genes in ExAC (Continued)
SCN5A Dominant 9 - - - -
TRDN Recessive 6 1 2 - -
All NMDpositive variants for genes associated with hereditary cancer, primary
ciliary dyskinesia, and arrhythmia/cardiomyopathy were binned based on their
allele frequencies in the ExAC dataset. In all genes listed, loss of protein
function has been established as the mechanism of disease. Several of the
genes listed are associated with both dominant and recessive inheritance
patterns; the listed inheritance patterns are specifically for those associated
with the disorders most relevant to the clinical area, and the mechanism of
disease is loss of function. For example, BRCA2 is associated with autosomal
dominant hereditary breast and ovarian cancer, as well as autosomal recessive
Fanconi anemia. DES and DSP genes are associated with both dominant and
recessive arrhythmia and cardiomyopathy disorders. However, the loss-of-
function mechanism has only been firmly established with the
recessive disorders
Kobayashi et al. Genome Medicine  (2017) 9:13 Page 7 of 14
Table 3 ExAC allele frequencies of the 74 hypertrophic cardiomyopathy “gold standard” missense variants
Gene Variant Effect Classification MAF
MYBPC3 NM_000256.3:c.772G > A p.Glu258Lys Pathogenic 0.0039%a
MYH7 NM_000257.2:c.2389G > A p.Ala797Thr Pathogenic 0.0033%
MYBPC3 NM_000256.3:c.1504C > T p.Arg502Trp Pathogenic 0.0025%
MYH7 NM_000257.2:c.2167C > T p.Arg723Cys Pathogenic 0.0025%
TNNI3 NM_000363.4:c.485G > A p.Arg162Gln Pathogenic 0.0025%
MYH7 NM_000257.2:c.1988G > A p.Arg663His Pathogenic 0.0016%
MYBPC3 NM_000256.3:c.1484G > A p.Arg495Gln Pathogenic 0.00083%
MYL2 NM_000432.3:c.173G > A p.Arg58Gln Pathogenic 0.00083%
MYL2 NM_000432.3:c.64G > A p.Glu22Lys Pathogenic 0.00083%
TNNI3 NM_000363.4:c.433C > T p.Arg145Trp Pathogenic 0.00083%
MYH7 NM_000257.2:c.2609G > A p.Arg870His Pathogenic 0.00082%b
TNNT2 NM_001001430.1:c.274C > T p.Arg92Trp Pathogenic 0.00082%
TNNI3 NM_000363.4:c.433C > G p.Arg145Gly Pathogenic 0.00080%
MYBPC3 NM_000256.3:c.1351G > C p.Glu451Gln Pathogenic 0
MYBPC3 NM_000256.3:c.1505G > A p.Arg502Gln Pathogenic 0
MYBPC3 NM_000256.3:c.2265C > A p.Asn755Lys Pathogenic 0
MYH7 NM_000257.2:c.1207C > T p.Arg403Trp Pathogenic 0
MYH7 NM_000257.2:c.1208G > A p.Arg403Gln Pathogenic 0
MYH7 NM_000257.2:c.1357C > T p.Arg453Cys Pathogenic 0
MYH7 NM_000257.2:c.1750G > C p.Gly584Arg Pathogenic 0
MYH7 NM_000257.2:c.1816G > A p.Val606Met Pathogenic 0
MYH7 NM_000257.2:c.2146G > A p.Gly716Arg Pathogenic 0
MYH7 NM_000257.2:c.2155C > T p.Arg719Trp Pathogenic 0
MYH7 NM_000257.2:c.2156G > A p.Arg719Gln Pathogenic 0
MYH7 NM_000257.2:c.2167C > G p.Arg723Gly Pathogenic 0
MYH7 NM_000257.2:c.2221G > T p.Gly741Trp Pathogenic 0
MYH7 NM_000257.2:c.2717A > G p.Asp906Gly Pathogenic 0
MYH7 NM_000257.2:c.2722C > G p.Leu908Val Pathogenic 0
MYH7 NM_000257.2:c.2770G > A p.Glu924Lys Pathogenic 0
MYH7 NM_000257.2:c.2788G > A p.Glu930Lys Pathogenic 0
MYH7 NM_000257.2:c.4135G > A p.Ala1379Thr Pathogenic 0
MYH7 NM_000257.2:c.438G > T p.Lys146Asn Pathogenic 0
MYH7 NM_000257.2:c.767G > A p.Gly256Glu Pathogenic 0
TNNI3 NM_000363.4:c.470C > T p.Ala157Val Pathogenic 0
TNNI3 NM_000363.4:c.557G > A p.Arg186Gln Pathogenic 0
TNNI3 NM_000363.4:c.575G > A p.Arg192His Pathogenic 0
TNNT2 NM_001001430.1:c.236 T > A p.Ile79Asn Pathogenic 0
TNNT2 NM_001001430.1:c.275G > A p.Arg92Gln Pathogenic 0
TNNT2 NM_001001430.1:c.421C > T p.Arg141Trp Pathogenic 0
TPM1 NM_000366.5:c.523G > A p.Asp175Asn Pathogenic 0
TPM1 NM_000366.5:c.688G > A p.Asp230Asn Pathogenic 0
MYBPC3 NM_000256.3:c.2686G > A p.Val896Met Likely benign 1.28%a
MYBPC3 NM_000256.3:c.833G > A p.Gly278Glu Likely benign 0.29%a
TNNI3 NM_000363.4:c.244C > T p.Pro82Ser Likely benign 0.28%
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pathogenic variants had been reported in at least one
published study (Fig. 3a). The median value was 29 pub-
lications and 20 of these variants were described in more
than 100 publications. For comparison, the analysis was
repeated for a selection of 100 variants with a ClinVar
consensus classification of benign. This set was deliber-
ately restricted to match the allele frequency range of
the 129 consensus pathogenic variants but was otherwise
randomly chosen. Among these benign variants, 47 had
zero publications and three-fourths had fewer than five
publications. For pathogenic variants, a statistically sig-
nificant but weak correlation was found between allele
frequency and publication counts (r = 0.24, p < 0.0063),
whereas no correlation was observed for benign variants
(r = –0.03) (Fig. 3b). This difference is the result of a
striking enrichment of publications among pathogenic
variants compared with benign variants (p < 2.2E-16;
Wilcoxon rank-sum test). These data suggest that patho-
genic variants as rare as 0.01% are routinely observed
and published and that the scientific literature can and
should be used in concert with population data for vari-
ant classification.
Discussion
Traditional methods for setting allele frequency thresh-
olds for variant classification are based on the expected
incidence of disease [4]. However, except for a handful
of extremely well-studied and relatively common
Table 3 ExAC allele frequencies of the 74 hypertrophic cardiomyopathy “gold standard” missense variants (Continued)
MYBPC3 NM_000256.3:c.565G > A p.Val189Ile Likely benign 0.27%
MYBPC3 NM_000256.3:c.3413G > A p.Arg1138His Likely benign 0.13%
MYBPC3 NM_000256.3:c.1519G > A p.Gly507Arg Likely benign 0.068%
MYBPC3 NM_000256.3:c.3004C > T p.Arg1002Trp Likely benign 0.067%
TNNI3 NM_000363.4:c.235C > T p.Arg79Cys Likely benign 0.043%
MYBPC3 NM_000256.3:c.1564G > A p.Ala522Thr Likely benign 0.039%
MYBPC3 NM_000256.3:c.440C > T p.Pro147Leu Likely benign 0.038%a
MYH7 NM_000257.2:c.3981C > A p.Asn1327Lys Likely benign 0.010%
MYBPC3 NM_000256.3:c.1147C > G p.Leu383Val Likely benign 0.0089%
MYBPC3 NM_000256.3:c.842G > A p.Arg281Gln Likely benign 0.0070%a
MYBPC3 NM_000256.3:c.1633C > A p.Leu545Met Likely benign 0.0034%
MYBPC3 NM_000256.3:c.1246G > A p.Gly416Ser Likely benign 0.0029%
MYBPC3 NM_000256.3:c.2063C > A p.Thr688Lys Likely benign 0.0019%a
MYBPC3 NM_000256.3:c.3142C > T p.Arg1048Cys Likely benign 0.0017%
TNNT2 NM_001001430.1:c.805A > T p.Asn269Tyr Likely benign 0.0017%a
MYBPC3 NM_000256.3:c.2410C > A p.Leu804Met Likely benign 0
MYH7 NM_000257.2:c.321 T > G p.Asp107Glu Likely benign 0
MYH7 NM_000257.2:c.4555A > T p.Ser1519Cys Likely benign 0
MYH7 NM_000257.2:c.8A > C p.Asp3Ala Likely benign 0
TNNI3 NM_000363.4:c.244C > A p.Pro82Thr Likely benign 0
TNNI3 NM_000363.4:c.253 T > A p.Leu85Met Likely benign 0
TNNI3 NM_000363.4:c.257C > A p.Ala86Asp Likely benign 0
TNNT2 NM_001001430.1:c.682C > G p.Gln228Glu Likely benign 0
MYBPC3 NM_000256.3:c.706A > G p.Ser236Gly Benign 10.79%
MYBPC3 NM_000256.3:c.472G > A p.Val158Met Benign 9.04%a
TNNT2 NM_001001430.1:c.758A > G p.Lys253Arg Benign 5.07%
MYH7 NM_000257.2:c.4472C > G p.Ser1491Cys Benign 0.75%
MYBPC3 NM_000256.3:c.977G > A p.Arg326Gln Benign 0.55%
MYBPC3 NM_000256.3:c.1144C > T p.Arg382Trp Benign 0.42%
MYBPC3 NM_000256.3:c.2498C > T p.Ala833Val Benign 0.22%
Jordan et al. [28] previously published a curated list of 74 “gold standard” missense variants in genes associated with hypertrophic cardiomyopathy. All pathogenic
variants were observed at allele frequencies of less than 0.005% in the ExAC dataset
aLoci covered by less than 80,000 total alleles in ExAC
bA variant that did not pass the variant calling quality filter in ExAC
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diseases, accurate incidence and penetrance numbers
simply do not exist. Furthermore, the numbers that are
available are undermined by selection bias, uncertainty
about the phenotypic heterogeneity derived from patho-
genic variants in the gene, uncertainty about how many
different pathogenic alleles account for the total inci-
dence of disease, and for many rare diseases, the relative
paucity of identified cases. Meaningful calculations can-
not be performed with inaccurate constants.
In this study, we suggest a bottom-up approach—de-
fining allele frequency thresholds through an empirical
analysis of the burden of pathogenic variants in a par-
ticular dataset—rather than the theoretical approach of
beginning with an assessment of disease incidence and
penetrance. We evaluated the pathogenic variant load in
ExAC on a gene-by-gene basis to determine the thresh-
olds at which a variant might be considered to be either
“within the pathogenic range” or where they might be
considered extremely unlikely to be pathogenic. In all of
the evaluated genes, which spanned multiple clinical
areas, levels of penetrance, ages of onset, rates of disease
prevalence and modes of inheritance, we found that the
vast majority of NMDpositive variants were extremely
rare, with 97.3% of them being observed with MAFs of
less than 0.01% in the ExAC cohort. We also observed
that pathogenic NMDnegative variants displayed equiva-
lent frequency distributions. Therefore, by relying on
NMDpositive variants as a representative subset of all
A
B
Fig. 3 Number of publications for variants observed at an allele frequency greater than 0.01%. a The top box plot, in blue, summarizes the
publication of a randomly selected set of 100 variants with a consensus classification of benign in ClinVar and having an allele frequency greater
than 0.01%. The bottom box plot, in red, summarizes the publication counts of all 129 variants with a consensus classification of pathogenic in
ClinVar and having an allele frequency greater than 0.01%. The box represents the 25th–75th percentile range, with the median publication count
depicted as the horizontal line in the middle. The “whiskers” represents the maximum and minimum values. b Scatter plot of allele frequencies and
publication counts of the same set of variants. Each red circle represents a pathogenic variant and each blue circle represents a benign variant. x-axis:
allele frequency; y-axis: publication counts. Four pathogenic variants that are extreme outliers were excluded for display purposes: (1) GJB2 NM_004004.5:
c.35delG (p.Gly12Valfs*2) has an allele frequency of 0.60% and reported in 496 publications; (2) CFTR NM_000492.3:c.1521_1523delCTT (p.Phe508del) has
an allele frequency of 0.68% and reported in 966 publications; (3) SERPINA1 NM_001127701.1:c.1096G > A (p.Glu366Lys) has an allele frequency of 1.2%
and reported in 56 publications; and (4) BTD NM_000060.3:c.1330G > C (p.Asp444His) has an allele frequency of 3.2% and reported in 46 publications
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pathogenic variants, we were able to apply this approach
to a broad set of genes regardless of how many variants
had been published in the public domain. This result is
consistent with our understanding that these diseases
are rare and typically caused by many individually
rare or private variants rather than a few common
variants [32, 33].
However, because of its reliance on NMDpositive vari-
ants, this gene-by-gene examination is restricted to dis-
eases for which the disease mechanism has been
confirmed to be loss of function. As we encountered
with hypertrophic cardiomyopathy, this limitation adds
challenges for diseases with gain-of-function mecha-
nisms. Moreover, although setting gene-specific allele
frequency thresholds is theoretically possible, such an
approach is likely impractical in a clinical laboratory set-
ting where hundreds or thousands of genes are simul-
taneously evaluated. As such, a hybrid approach may be
warranted when the types of observations made in this
study are combined with our, albeit limited, understand-
ing of disease incidence and penetrance. In this study,
we deliberately examined sets of genes expected to have
relatively high observations of pathogenic variants in the
ExAC cohort, whether due to high disease incidence,
low penetrance, recessive conditions, or potential en-
richment in the ExAC cohort. Therefore, an allele fre-
quency threshold derived from this set of genes can be
considered the “upper-bound” for all other genes with
lower incidences and/or higher penetrance.
The presence of founder mutations remains a concern
in any approach based on population frequency, includ-
ing the method presented herein; however, the risk is
mitigated by the well-studied nature of most of the sub-
populations in the ExAC database. Indeed, all pathogenic
variants we examined that had MAFs greater than 0.01%
have been previously reported in the published litera-
ture. As such, comprehensive literature reviews of vari-
ants at these higher MAF ranges still remain an essential
component of variant classification. While this is not a
significant hurdle for targeted testing approaches in
which literature review is routine, it is an important con-
sideration for whole-genome and whole-exome studies
in which variants are often filtered by MAF. Of note, be-
nign variants in the same MAF range had on average
12-fold fewer publications and nearly half of these vari-
ants have never been reported in the literature. This sug-
gests that the necessary burden of reviewing literature
on these benign variants is minimal.
For this study, we did not consider ethnic subpopula-
tion data. This was a deliberate decision based on our
initial observation that most pathogenic variants are ex-
tremely rare in the overall global population. Given the
large variability in the cohort sizes of various ethnic
groups represented in ExAC, subdividing the frequency
data would have added complexities that were extrane-
ous to the aims of this study. However, subpopulation-
specific allele frequency data remain invaluable tools for
identifying population-specific polymorphisms as well as
putative founder mutations. Indeed, recent publications
have successfully used ExAC subpopulation data to
identify cases of genetic misdiagnosis; these variants
were previously classified as pathogenic, but are now
believed to be benign polymorphisms that are over-
represented in certain ethnic groups [7, 34].
The pathogenic allele frequency distributions de-
scribed in this study are specific to the ExAC cohort, but
the approach is generalizable. The allele frequencies of
variants are a function of the fitness burden of the vari-
ant as well as any skewing that results from non-random
selection of the cohort, which can include factors such
as ethnic composition or potential enrichment for par-
ticular diseases based on study design. These would all
be considered confounding factors in traditional ap-
proaches to MAF threshold calculations. However,
because our method measures allele frequency distribu-
tions directly, these factors are no longer significant con-
cerns; this is the key advantage of this approach
compared with calculations based simply on disease inci-
dence and penetrance. The implication of this direct ap-
proach is that MAF thresholds can and should be
reconsidered for each population dataset. This is a scal-
able approach that allows for rapid adoption of new
datasets and refinements to MAF thresholds as larger
and higher-quality datasets are published.
Analyzing the burden of genetic variation in and of it-
self is not a novel concept. Previous works that mea-
sured residual variation intolerance scores (RVIS) and
probability of being loss-of-function intolerant (pLI)
played important roles in identifying genes of clinical
importance [5, 35]. By examining the ratio of observed
and expected number of genetic variations, these ap-
proaches gave clinical geneticists the ability to detect sig-
natures of selection on a gene-by-gene basis: genes with
less observed variation than expected are likely to be
subject to purifying selection. The study presented in
this manuscript is, in spirit, a continuation of those
works. Here, we evaluated the observed genetic vari-
ation, which is the outcome of selection occurring on
disease-causing variants, to answer the question of what
variant frequency is sufficient to designate the variant as
too common to cause disease.
Finally, this study was almost entirely dependent on
shared data (ExAC and ClinVar). As researchers and
clinical laboratories share more data and work collabora-
tively, we anticipate that the collective knowledge and
experiences will greatly improve the community’s ability
to classify variants accurately, which will in turn lead to
better patient care.
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Conclusions
In clinical genetics, variant classification is a complex
process involving the evaluation and interpretation of
multiple pieces of evidence, which in turn requires consid-
erable knowledge and expertise. A variant’s absence from
ExAC or presence in ExAC at very low frequency is clearly
not sufficient to indicate that the variant is pathogenic.
Many variants are private, novel, or rare, and the vast ma-
jority of these are also not pathogenic. However, with cer-
tain clear exceptions such as founder mutations, the rarity
of the variant is a prerequisite for pathogenicity.
As mentioned above, in the joint consensus recom-
mendation for the interpretation of sequence variants by
the ACMG and AMP, it is stated that an “allele fre-
quency greater than expected for disorder” should be
considered strong evidence for a benign classification.
Based on the observations made in this study, global
ExAC allele frequencies greater than 0.01% should be
considered “greater than expected” for diseases of Men-
delian inheritance and this threshold may be lowered
even further for certain genes such as BRCA1 and
BRCA2. Ultimately, however, a benign or likely benign
classification should be made in the context of allele fre-
quency, reports in the published literature, and the con-
fidence of the underlying data. The method outlined in
this study is intended to assist clinical geneticists in bet-
ter evaluating and using large population datasets.
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